Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Subscribe To Our Newsletter & Stay Updated